An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease
Clinical trial NCT05174039 · COMPLETED
Trial details
- NCT number
- NCT05174039
- Sponsor
- Beyond Batten Disease Foundation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-10
- Primary completion
- 2024-05-30
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.